Transforming the Care of Patients with Diabetic Kidney Disease.

Clinical Journal of the American Society of Nephrology : CJASN
Frank C BrosiusDKD-Collaborative ASN Taskforce

Abstract

Diabetes and its associated complications pose an immediate threat to humankind. Diabetic kidney disease is one of the most devastating complications, increasing the risk of death more than ten-fold over the general population. Until very recently, the only drugs proven and recommended to slow the progression of diabetic kidney disease were angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers, which act by inhibiting the renin-angiotensin system. Despite their efficacy as kidney and cardiovascular protective therapies and as antihypertensive agents, renin-angiotensin system inhibitors have been grossly underutilized. Moreover, even when renin-angiotensin system inhibitors are used, patients still have a high residual risk of diabetic kidney disease progression. Finally, the kidney-protective effect of renin-angiotensin system inhibitors has been categorically demonstrated only in patients with macroalbuminuria included in the Irbesartan Diabetic Nephropathy Trial (IDNT) and Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trials, not in other individuals. The lack of new therapies to treat diabetic kidney disease over the past 2 decades has therefore represente...Continue Reading

References

Aug 20, 2011·Clinical Journal of the American Society of Nephrology : CJASN·Abeba M BerhaneRobert L Hanson
Dec 29, 2011·Medical Care Research and Review : MCRR·Byron J PowellJennifer L York
Mar 14, 2014·Journal of Cardiovascular Pharmacology·Peter KolkhofStefan Schäfer
Jun 4, 2014·The Journal of Clinical Investigation·Kimberly ReidyKatalin Susztak
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Nov 17, 2015·Journal of Clinical Medicine·Luz Lozano-Maneiro, Adriana Puente-García
May 11, 2016·JAMA : the Journal of the American Medical Association·David A ChambersMuin J Khoury
Aug 31, 2017·The New England Journal of Medicine·Johannes F E MannUNKNOWN LEADER Steering Committee and Investigators
Mar 28, 2018·Advances in Chronic Kidney Disease·Digsu N KoyeMeda E Pavkov
Nov 13, 2018·The New England Journal of Medicine·Stephen D WiviottUNKNOWN DECLARE–TIMI 58 Investigators
Dec 14, 2018·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Akira Nishiyama
Jan 23, 2019·Diabetes·Radica Z AlicicKatherine R Tuttle
Apr 17, 2019·The New England Journal of Medicine·Vlado PerkovicUNKNOWN CREDENCE Trial Investigators
Aug 7, 2019·Cardiovascular Diabetology·Aaron Y KlugerPeter A McCullough
Sep 20, 2019·The New England Journal of Medicine·John J V McMurrayUNKNOWN DAPA-HF Trial Committees and Investigators
Oct 9, 2019·Clinical Journal of the American Society of Nephrology : CJASN·Alan S KligerUNKNOWN Diabetic Kidney Disease Task Force of the American Society of Nephrology
Nov 7, 2019·Cell Metabolism·Deepak L BhattEugene Braunwald
Apr 20, 2020·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Chi D ChuUNKNOWN Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team
Jul 9, 2020·Canadian Journal of Kidney Health and Disease·Lisa DubrofskyDavid Z Cherney
Sep 1, 2020·The New England Journal of Medicine·Milton PackerUNKNOWN EMPEROR-Reduced Trial Investigators
Sep 24, 2020·The New England Journal of Medicine·Christopher P CannonUNKNOWN VERTIS CV Investigators
Sep 25, 2020·The New England Journal of Medicine·Hiddo J L HeerspinkUNKNOWN DAPA-CKD Trial Committees and Investigators
Sep 29, 2020·Circulation·Janani RangaswamiUNKNOWN American Heart Association Council on the Kidney in Cardiovascular Disease; Council on Arteriosclerosis, Thrombosis and Vasc
Dec 3, 2020·The New England Journal of Medicine·George L BakrisUNKNOWN FIDELIO-DKD Investigators
Jan 30, 2021·Kidney International·Katherine R Tuttle, David Z I Cherney
Feb 5, 2021·Clinical Journal of the American Society of Nephrology : CJASN·Sophia Zoungas, Ian H de Boer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
Anthony J BleyerJeffrey R Schelling
International Urology and Nephrology
Elias A T KochNakhoul Nakhoul
Clinical Journal of the American Society of Nephrology : CJASN
Allon N Friedman, Bruce Wolfe
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension
E RitzG Miltenberger-Miltenyi
© 2021 Meta ULC. All rights reserved